

Paris, June 29th 2015

Quantum Genomics obtains positive results with heart failure study in dogs

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that the study for the prevention and treatment of heart failure in dogs has been completed within the projected timeline.

The results show a statistically significant improvement during the fourth week in the cardiac ejection fraction in dogs treated over a 28-day period compared to untreated dogs.

These particularly promising results reinforce the positive data previously obtained in rats in a study at the Center for Interdisciplinary Research in Biology (Inserm U1050/CNRS UMR 7241) at College de France (Paris) and at the University of Ottawa Heart Institute, by teams led by Dr Llorens-Cortès (Prix Galien 2014) and Prof Leenen (*Cardiovascular Research* 2013, vol. 97 (3), 424-431), respectively.

It reinforces the pertinence of the development of brain aminopeptidase A inhibitors (BAPAs), in animal and human health, for the treatment of heart failure.

Quantum Genomics points out that this study in dogs was carried out as part of the collaboration agreement with licensing option signed with a major company in the field of animal health.

The pharmaceutical partner now has six months to exercise the option to continue development and market the future animal health drug under a license agreement to be negotiated with Quantum Genomics.

CONTACTS

Quantum Genomics

Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77

Quantum Genomics

Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com

ACTUS finance & communication

Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).